Literature DB >> 13373238

The experimental evaluation of antiparkinsonian compounds.

K R UNNA, V G VERNIER.   

Abstract

Keywords:  PARALYSIS AGITANS/therapy

Mesh：

Substances：

Year:  1956        PMID： 13373238     DOI： 10.1111/j.1749-6632.1956.tb36841.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  6 in total

1.  The pathogenesis of Parkinson's disease: a new hypothesis.

Authors:  A BARBEAU
Journal:  Can Med Assoc J       Date:  1962-10-13       Impact factor: 8.262

2.  Differential impairment of delayed matching in monkeys by scopolamine and scopolamine methylbromide.

Authors:  Z Bohdanecký; M E Jarvik; J L Carley
Journal:  Psychopharmacologia       Date:  1967

Review 3.  Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders.

Authors:  Mark S Moehle; P Jeffrey Conn
Journal:  Mov Disord       Date:  2019-06-18       Impact factor: 10.338

4.  Antagonism of the effects of tremorine by tropine derivatives.

Authors:  M E FARQUHARSON; R G JOHNSTON
Journal:  Br J Pharmacol Chemother       Date:  1959-12

5.  Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor.

Authors:  Mark S Moehle; Tristano Pancani; Nellie Byun; Samantha E Yohn; George H Wilson; Johnathan W Dickerson; Daniel H Remke; Zixiu Xiang; Colleen M Niswender; Jürgen Wess; Carrie K Jones; Craig W Lindsley; Jerri M Rook; P Jeffrey Conn
Journal:  Neuron       Date:  2017-12-20       Impact factor: 17.173

6.  Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Robert A Koeppe; Carlos A Sanchez-Catasus; Kirk A Frey; Peter Scott; Gregory M Constantine; Roger L Albin; Martijn L T M Müller
Journal:  Brain Commun       Date:  2021-05-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.